Akcea Therapeutics Stock Price, News & Analysis (NASDAQ:AKCA)

$22.17 +0.32 (+1.46 %)
(As of 02/25/2018 09:01 AM ET)
Previous Close$22.17
Today's Range$21.21 - $22.58
52-Week Range$8.10 - $31.23
Volume233,474 shs
Average Volume218,952 shs
Market Capitalization$1.48 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Akcea Therapeutics (NASDAQ:AKCA)

Akcea Therapeutics logoAkcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).

Receive AKCA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKCA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKCA
CUSIPN/A
Phone617-207-0202

Debt

Debt-to-Equity RatioN/A
Current Ratio3.92%
Quick Ratio3.92%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees30
Outstanding Shares66,540,000

Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions

What is Akcea Therapeutics' stock symbol?

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

Where is Akcea Therapeutics' stock going? Where will Akcea Therapeutics' stock price be in 2018?

4 Wall Street analysts have issued 12-month price targets for Akcea Therapeutics' shares. Their predictions range from $20.00 to $27.00. On average, they expect Akcea Therapeutics' share price to reach $24.00 in the next year. View Analyst Ratings for Akcea Therapeutics.

Are investors shorting Akcea Therapeutics?

Akcea Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 5,141,576 shares, an increase of 34.6% from the January 12th total of 3,819,994 shares. Based on an average daily volume of 294,283 shares, the days-to-cover ratio is currently 17.5 days. Currently, 34.7% of the company's stock are short sold.

Who are some of Akcea Therapeutics' key competitors?

Who are Akcea Therapeutics' key executives?

Akcea Therapeutics' management team includes the folowing people:

  • Stanley T. Crooke M.D. Ph.D., Chairman of the Board (Age 72)
  • Paula Soteropoulos, President, Chief Executive Officer, Director (Age 49)
  • Michael Maclean, Chief Financial Officer (Age 52)
  • Jeffrey M. Goldberg, Chief Operating Officer (Age 44)
  • Elizabeth L. Hougen, Senior Vice President - Finance (Age 55)
  • Louis St. L. O'Dea, Chief Medical Officer (Age 66)
  • B. Lynne Parshall J.D., Director (Age 63)
  • Edward M. Fitzgerald, Independent Director (Age 62)
  • Christopher Gabrieli M.D., Independent Director (Age 57)
  • Elaine Hochberg, Independent Director (Age 59)

When did Akcea Therapeutics IPO?

(AKCA) raised $125 million in an IPO on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.

When did the company's lock-up period expire?

Akcea Therapeutics' lock-up period expired on Wednesday, January 10th. Akcea Therapeutics had issued 15,625,000 shares in its initial public offering on July 14th. The total size of the offering was $125,000,000 based on an initial share price of $8.00. Since the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Who owns Akcea Therapeutics stock?

Akcea Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.74%), Geode Capital Management LLC (0.31%), Altrinsic Global Advisors LLC (0.23%), Candriam Luxembourg S.C.A. (0.17%), Iguana Healthcare Management LLC (0.15%) and Schwab Charles Investment Management Inc. (0.10%). View Institutional Ownership Trends for Akcea Therapeutics.

Who sold Akcea Therapeutics stock? Who is selling Akcea Therapeutics stock?

Akcea Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A. and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Akcea Therapeutics.

Who bought Akcea Therapeutics stock? Who is buying Akcea Therapeutics stock?

Akcea Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Iguana Healthcare Management LLC, Goldman Sachs Group Inc., Swiss National Bank, Altrinsic Global Advisors LLC, Wells Fargo & Company MN, Alliancebernstein L.P. and Virtus Fund Advisers LLC. View Insider Buying and Selling for Akcea Therapeutics.

How do I buy Akcea Therapeutics stock?

Shares of Akcea Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Akcea Therapeutics' stock price today?

One share of Akcea Therapeutics stock can currently be purchased for approximately $22.17.

How big of a company is Akcea Therapeutics?

Akcea Therapeutics has a market capitalization of $1.48 billion. Akcea Therapeutics employs 30 workers across the globe.

How can I contact Akcea Therapeutics?

Akcea Therapeutics' mailing address is 55 CAMBRIDGE PARKWAY SUITE 100, CAMBRIDGE MA, 92010. The company can be reached via phone at 617-207-0202 or via email at [email protected]


MarketBeat Community Rating for Akcea Therapeutics (AKCA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  95 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  190
MarketBeat's community ratings are surveys of what our community members think about Akcea Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Akcea Therapeutics (NASDAQ:AKCA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.00$24.00$24.00$23.67
Price Target Upside: 44.49% upside44.49% upside44.49% upside58.84% upside

Akcea Therapeutics (NASDAQ:AKCA) Consensus Price Target History

Price Target History for Akcea Therapeutics (NASDAQ:AKCA)

Akcea Therapeutics (NASDAQ:AKCA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/7/2017Stifel NicolausReiterated RatingBuy -> Buy$19.00 -> $20.00N/AView Rating Details
10/31/2017CowenReiterated RatingBuyN/AView Rating Details
8/8/2017BMO Capital MarketsInitiated CoverageOutperform$25.00MediumView Rating Details
8/8/2017Wells Fargo & CoInitiated CoverageOutperform -> Outperform$27.00MediumView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Akcea Therapeutics (NASDAQ:AKCA) Earnings History and Estimates Chart

Earnings by Quarter for Akcea Therapeutics (NASDAQ:AKCA)

Akcea Therapeutics (NASDAQ AKCA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017($0.21)($0.18)$15.48 million$13.45 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.27)$14.13 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Akcea Therapeutics (NASDAQ:AKCA) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.22 EPS
Next Year EPS Consensus Estimate: $-1.21 EPS

Dividends

Dividend History for Akcea Therapeutics (NASDAQ:AKCA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Akcea Therapeutics (NASDAQ AKCA) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 28.29%
Insider Trades by Quarter for Akcea Therapeutics (NASDAQ:AKCA)
Institutional Ownership by Quarter for Akcea Therapeutics (NASDAQ:AKCA)

Akcea Therapeutics (NASDAQ AKCA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/19/2017Ionis Pharmaceuticals IncMajor ShareholderBuy3,125,000$8.00$25,000,000.0028,884,540View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Akcea Therapeutics (NASDAQ AKCA) News Headlines

Source:
DateHeadline
Akcea Therapeutics (AKCA) Lowered to "Hold" at BidaskClubAkcea Therapeutics (AKCA) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - February 21 at 11:10 PM
Akcea Therapeutics Inc (AKCA) Given Average Recommendation of "Buy" by BrokeragesAkcea Therapeutics Inc (AKCA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 18 at 1:30 AM
Akcea Therapeutics (AKCA) Announces FDA Panel Meeting to Review Volanesorsen as Treatment for Familial Chylomicronemia SyndromeAkcea Therapeutics (AKCA) Announces FDA Panel Meeting to Review Volanesorsen as Treatment for Familial Chylomicronemia Syndrome
www.streetinsider.com - February 16 at 9:09 AM
Akcea Announces FDA Advisory Committee Meeting to Review Volanesorsen as a Treatment for Familial Chylomicronemia SyndromeAkcea Announces FDA Advisory Committee Meeting to Review Volanesorsen as a Treatment for Familial Chylomicronemia Syndrome
finance.yahoo.com - February 15 at 4:34 PM
Akcea Therapeutics Inc (AKCA) Sees Large Increase in Short InterestAkcea Therapeutics Inc (AKCA) Sees Large Increase in Short Interest
www.americanbankingnews.com - February 9 at 4:58 PM
Akcea Completes Enrollment in Phase 2b Study of AKCEA-APO(a)-LRxAkcea Completes Enrollment in Phase 2b Study of AKCEA-APO(a)-LRx
finance.yahoo.com - February 7 at 9:12 AM
Akcea Therapeutics Inc (AKCA) Receives Average Rating of "Buy" from AnalystsAkcea Therapeutics Inc (AKCA) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - January 24 at 1:44 AM
Akcea Therapeutics (AKCA) Raised to "Hold" at BidaskClubAkcea Therapeutics (AKCA) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - January 20 at 12:33 PM
BidaskClub Downgrades Akcea Therapeutics (AKCA) to SellBidaskClub Downgrades Akcea Therapeutics (AKCA) to Sell
www.americanbankingnews.com - January 6 at 8:52 PM
Akcea Therapeutics (AKCA) Commences Phase 2b Study of AKCEA-APOCIII-LRx in Patients with Hypertriglyceridemia and Established Cardiovascular DiseaseAkcea Therapeutics (AKCA) Commences Phase 2b Study of AKCEA-APOCIII-LRx in Patients with Hypertriglyceridemia and Established Cardiovascular Disease
www.streetinsider.com - January 6 at 9:00 AM
Akcea Initiates Phase 2b Study of AKCEA-APOCIII-LRx in Patients with Hypertriglyceridemia and Established Cardiovascular DiseaseAkcea Initiates Phase 2b Study of AKCEA-APOCIII-LRx in Patients with Hypertriglyceridemia and Established Cardiovascular Disease
finance.yahoo.com - January 5 at 5:34 PM
Akcea Therapeutics (AKCA) Cut to Hold at Zacks Investment ResearchAkcea Therapeutics (AKCA) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - January 5 at 4:52 PM
Akcea Therapeutics Incs Lock-Up Period Set To End  on January 10th (NASDAQ:AKCA)Akcea Therapeutics Inc's Lock-Up Period Set To End on January 10th (NASDAQ:AKCA)
www.americanbankingnews.com - January 3 at 1:22 AM
Akcea Therapeutics (AKCA) Stock Rating Upgraded by Zacks Investment ResearchAkcea Therapeutics (AKCA) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 2 at 6:46 PM
Akcea Therapeutics (AKCA) Cut to "Hold" at BidaskClubAkcea Therapeutics (AKCA) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - December 30 at 3:38 PM
Akcea Therapeutics Inc (AKCA) Receives Average Recommendation of "Buy" from BrokeragesAkcea Therapeutics Inc (AKCA) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 30 at 1:48 PM
Zacks: Akcea Therapeutics Inc (AKCA) Receives Average Recommendation of "Strong Buy" from BrokeragesZacks: Akcea Therapeutics Inc (AKCA) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - December 28 at 1:38 AM
Critical Comparison: Opko Health (OPK) vs. Akcea Therapeutics (AKCA)Critical Comparison: Opko Health (OPK) vs. Akcea Therapeutics (AKCA)
www.americanbankingnews.com - December 23 at 7:24 PM
Quotidian Technical Highlights on Selected Biotech Stocks -- Amgen ... - PR Newswire (press release)Quotidian Technical Highlights on Selected Biotech Stocks -- Amgen ... - PR Newswire (press release)
www.prnewswire.com - December 14 at 9:01 AM
Akcea Therapeutics (AKCA) Commences Phase 2 Study of AKCEA ... - StreetInsider.comAkcea Therapeutics (AKCA) Commences Phase 2 Study of AKCEA ... - StreetInsider.com
www.streetinsider.com - December 14 at 9:01 AM
Akcea Initiates Phase 2 Study of AKCEA-ANGPTL3-LRx in Patients with Hypertriglyceridemia, Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (NAFLD)Akcea Initiates Phase 2 Study of AKCEA-ANGPTL3-LRx in Patients with Hypertriglyceridemia, Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (NAFLD)
finance.yahoo.com - December 14 at 9:01 AM
Zacks: Akcea Therapeutics Inc (AKCA) Given $24.00 Consensus Price Target by BrokeragesZacks: Akcea Therapeutics Inc (AKCA) Given $24.00 Consensus Price Target by Brokerages
www.americanbankingnews.com - December 10 at 5:20 PM
Akcea to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference - GlobeNewswire (press release)Akcea to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - December 7 at 6:24 PM
Akcea to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare ConferenceAkcea to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 7 at 8:57 AM
Akcea Therapeutics (AKCA) versus Its Competitors Head-To-Head ContrastAkcea Therapeutics (AKCA) versus Its Competitors Head-To-Head Contrast
www.americanbankingnews.com - December 6 at 1:28 AM
Akcea Therapeutics, Inc. Fundamental Analysis : November 30, 2017Akcea Therapeutics, Inc. Fundamental Analysis : November 30, 2017
finance.yahoo.com - November 30 at 5:49 PM
Zacks: Akcea Therapeutics, Inc. (AKCA) Receives Consensus Recommendation of "Strong Buy" from BrokeragesZacks: Akcea Therapeutics, Inc. (AKCA) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - November 25 at 3:50 AM
Zacks: Akcea Therapeutics, Inc. (AKCA) Given Consensus Rating of "Strong Buy" by AnalystsZacks: Akcea Therapeutics, Inc. (AKCA) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - November 19 at 3:48 PM
Contrasting Akcea Therapeutics (AKCA) & Its PeersContrasting Akcea Therapeutics (AKCA) & Its Peers
www.americanbankingnews.com - November 16 at 7:10 PM
Akcea and Ionis Announce Acceptance of Marketing Applications in U.S., EU and Canada for Volanesorsen for the Treatment of FCSAkcea and Ionis Announce Acceptance of Marketing Applications in U.S., EU and Canada for Volanesorsen for the Treatment of FCS
finance.yahoo.com - November 16 at 10:57 AM
Akcea Therapeutics, Inc. (AKCA) Stock Rating Upgraded by Zacks Investment ResearchAkcea Therapeutics, Inc. (AKCA) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 9 at 6:28 PM
Akcea to Present at Stifel 2017 Healthcare ConferenceAkcea to Present at Stifel 2017 Healthcare Conference
finance.yahoo.com - November 7 at 5:15 PM
Akcea Therapeutics reports 3Q lossAkcea Therapeutics reports 3Q loss
finance.yahoo.com - November 6 at 9:31 PM
Akcea Reports Financial Results and Highlights for Third Quarter 2017Akcea Reports Financial Results and Highlights for Third Quarter 2017
finance.yahoo.com - November 6 at 4:29 PM
Zacks: Akcea Therapeutics, Inc. (AKCA) Receives Average Rating of "Strong Buy" from AnalystsZacks: Akcea Therapeutics, Inc. (AKCA) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - November 4 at 1:38 AM
Two Boston-area biotechs raise combined $152M in IPOsTwo Boston-area biotechs raise combined $152M in IPOs
finance.yahoo.com - November 2 at 4:04 PM
AZN Gets Speedy Nod, RBP-6000 Just One Step Away From Approval, STML SoarsAZN Gets Speedy Nod, RBP-6000 Just One Step Away From Approval, STML Soars
www.rttnews.com - November 1 at 2:58 AM
Akcea and Ionis Report Positive Phase 1/2a Data with AKCEA-APOCIII-LRxAkcea and Ionis Report Positive Phase 1/2a Data with AKCEA-APOCIII-LRx
finance.yahoo.com - October 31 at 4:53 PM
Cowen and Company Reaffirms "Buy" Rating for Akcea Therapeutics, Inc. (AKCA)Cowen and Company Reaffirms "Buy" Rating for Akcea Therapeutics, Inc. (AKCA)
www.americanbankingnews.com - October 31 at 2:40 PM
Akcea Therapeutics Named Among Top 100 Women-Led Businesses in Massachusetts for Second Consecutive YearAkcea Therapeutics Named Among Top 100 Women-Led Businesses in Massachusetts for Second Consecutive Year
finance.yahoo.com - October 27 at 5:48 PM
Akcea Therapeutics to Hold Third Quarter 2017 Financial Results WebcastAkcea Therapeutics to Hold Third Quarter 2017 Financial Results Webcast
finance.yahoo.com - October 23 at 4:47 PM
 Akcea Therapeutics, Inc. (AKCA) Receives Consensus Recommendation of "Strong Buy" from Analysts Akcea Therapeutics, Inc. (AKCA) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - October 20 at 2:46 AM
Akcea Presents Data Demonstrating Significant Burden of Illness in Familial Chylomicronemia SyndromeAkcea Presents Data Demonstrating Significant Burden of Illness in Familial Chylomicronemia Syndrome
finance.yahoo.com - October 16 at 4:34 PM
Akcea Therapeutics, Inc. (AKCA) Cut to Sell at Zacks Investment ResearchAkcea Therapeutics, Inc. (AKCA) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - October 10 at 8:56 PM
AKCEA THERAPEUTICS INCAKCEA THERAPEUTICS INC
www.finanznachrichten.de - October 10 at 5:05 PM
Akcea Therapeutics Volanesorsen Receives Promising Innovative Medicine (PIM) Status for the Treatment of Familial Chylomicronaemia Syndrome (FCS)Akcea Therapeutics' Volanesorsen Receives Promising Innovative Medicine (PIM) Status for the Treatment of Familial Chylomicronaemia Syndrome (FCS)
www.nasdaq.com - October 10 at 5:05 PM
Akcea Therapeutics’ Volanesorsen Receives Promising Innovative Medicine (PIM) Status for the Treatment of Familial Chylomicronaemia Syndrome (FCS)Akcea Therapeutics’ Volanesorsen Receives Promising Innovative Medicine (PIM) Status for the Treatment of Familial Chylomicronaemia Syndrome (FCS)
finance.yahoo.com - October 10 at 2:46 AM
Zacks: Akcea Therapeutics, Inc. (AKCA) Receives Consensus Rating of "Strong Buy" from BrokeragesZacks: Akcea Therapeutics, Inc. (AKCA) Receives Consensus Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - October 7 at 10:40 AM
Akcea Therapeutics Canada Appoints Nelly Komari, B. Pharm., MSc. as Medical DirectorAkcea Therapeutics Canada Appoints Nelly Komari, B. Pharm., MSc. as Medical Director
finance.yahoo.com - October 4 at 2:42 PM
Akcea Therapeutics Inc. (AKCA) Sees Significant Growth in Short InterestAkcea Therapeutics Inc. (AKCA) Sees Significant Growth in Short Interest
www.americanbankingnews.com - September 29 at 1:56 AM

SEC Filings

Akcea Therapeutics (NASDAQ:AKCA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Akcea Therapeutics (NASDAQ:AKCA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Akcea Therapeutics (NASDAQ AKCA) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.